FREM2 and glioblastoma: Thus, we conclude that all three variants of FREM2 pathway activation are robust biomarkers for LGG and GBM discrimination, that have comparable performance with IDH mutation status, and significantly outperform MGMT methylation and FREM2 expression as the biomarkers.